MedTrace Logo

Effect of Whole Body Electromyostimulation and/or Protein Supplementation on Sarcopenic Obesity in 70+

NCT02857660 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2017-05-02

No results posted yet for this study

Summary

The aim of the study is to determine the effect of 16 weeks of Whole Body-Electromyostimulation (WB-EMS) and/or protein supplementation on Sarcopenic Obesity (SO) in community dwelling male subjects 70+ with SO .

108 eligible men will be randomly assigned to either a (1) WB-EMS and Protein (2) Protein (3) sedentary control group.

WB-EMS will be applied 1,5 x 20 min per week (i.e. 3 sessions in two weeks) with bipolar current, 85 Hz in an intermitted mode (4 s - 4 s of rest). Protein supplementation will be adjusted to dietary intake in order to reach a total protein intake between 1,5 - 1,7g/kg body-mass/d . Primary study endpoint will be the Sarcopenia Z-Score

Conditions

  • Sarcopenic Obesity

Interventions

OTHER

Whole body Electromyostimulation (exercise)

1.5 x 20 min/week (e.g. each Tuesday and every second Friday) with bipolar current, 85 Hz, 360 µs, rectangular mode, intermittent with 4 sec of current and 4 s of rest.

DIETARY_SUPPLEMENT

Protein

up to 1.5-1.7 g/kg bodymass/d of protein (whey protein)

Sponsors & Collaborators

  • University of Erlangen-Nürnberg Institute of Medical Physics

    collaborator UNKNOWN

  • University of Erlangen-Nürnberg Institute of Biomedicine of Aging

    collaborator UNKNOWN

  • University of Erlangen-Nürnberg Medical School

    lead OTHER

Principal Investigators

  • Cornel Sieber, MD · Institute of Biomedicine of Aging, University of Erlangen-Nürnberg

  • Klaus Engelke, PhD · University of Erlangen-Nürnberg Medical School

  • Ellen Freiberger, PhD · Institute of Biomedicine of Aging, University of Erlangen-Nürnberg

  • Anja Weissenfels, MA · University of Erlangen-Nürnberg Medical School

  • Wolfgang Kemmler, PhD · University of Erlangen-Nürnberg Medical School

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
70 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-08-31
Primary Completion
2017-02-28
Completion
2017-04-30

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02857660 on ClinicalTrials.gov